Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 4, 2014, Pages 531-541

  Daull, Philippe ^a   Lallemand, Frédéric ^a   Garrigue, Jean Sébastien ^a  

^a Novagali Pharma   (France)

Author keywords

cationic; cetalkonium chloride; drug delivery; ocular surface; oil in water emulsion

Indexed keywords

ADMINISTRATION, TOPICAL; BIOLOGICAL AVAILABILITY; CATIONS; DRUG DELIVERY SYSTEMS; EMULSIONS; EYE DISEASES; FATTY ALCOHOLS; HUMANS; OILS; OPHTHALMIC SOLUTIONS; QUATERNARY AMMONIUM COMPOUNDS; WATER;

EID: 84899078059     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12075     Document Type: Review

References (64)

1. Urtti A,. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006; 58: 1131-1135.
2. Kaur IP, etal. Vesicular systems in ocular drug delivery: an overview. Int J Pharm 2004; 269: 1-14.
3. du Toit LC, etal. Ocular drug delivery-a look towards nanobioadhesives. Expert Opin Drug Deliv 2011; 8: 71-94.
4. Abdelkader H, Alany RG,. Controlled and continuous release ocular drug delivery systems: pros and cons. Curr Drug Deliv 2012; 9: 421-430.
5. Muchtar S, etal. A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: effect on intraocular pressure in rabbits. Ophthalmic Res 1992; 24: 142-149.
6. Naveh N, etal. Pilocarpine incorporated into a submicron emulsion vehicle causes an unexpectedly prolonged ocular hypotensive effect in rabbits. J Ocul Pharmacol 1994; 10: 509-520.
7. Ding S, etal. Nonirritating Emulsions for Sensitive Tissues, I. Allergan. Patent No.: 5474979, 1995: US.
8. Vandamme TF,. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res 2002; 21: 15-34.
9. Tamilvanan S, Benita S,. The potential of lipid emulsion for ocular delivery of lipophilic drugs. Eur J Pharm Biopharm 2004; 58: 357-368.
10. Royle L, etal. Glycan structures of ocular surface mucins in man, rabbit and dog display species differences. Glycoconj J 2008; 25: 763-773.
11. Rabinovich-Guilatt L, etal. Cationic vectors in ocular drug delivery. J Drug Target 2004; 12: 623-633.
12. Klang S, etal. The stability of piroxicam incorporated in a positively-charged submicron emulsion for ocular administration. Int J Pharm 1996; 132: 33-44.
13. Klang S, etal. Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution. Pharm Dev Technol 2000; 5: 521-532.
14. Tamilvanan S, etal. Ocular delivery of cyclosporin A. I. Design and characterization of cyclosporin A-loaded positively-charged submicron emulsion. S.T.P. Pharma Sci 2001; 11: 421-426.
15. Benita S, Elbaz E,. Oil- in-Water Emulsions of Positively Charged Particles. Yisum Research Development Company of the Hebrew University of Jerusalem. Patent No.: US 6007826 A, 1993.
16. Campbell PI,. Toxicity of some charged lipids used in liposome preparations. Cytobios 1983; 37: 21-26.
17. Lallemand F, etal. Successfully improving ocular drug delivery using the cationic nanoemulsion novasorb. J Drug Deliv 2012; 2012: 604204.
18. Becher P,. Emulsions: Theory and Practice, 3rd edn. New York: Oxford University Press, 2001.
19. Rubino JT,. The influence of charged lipids on the flocculation and coalescence of oil-in-water emulsions. I: kinetic assessment of emulsion stability. J Parenter Sci Technol 1990; 44: 210-215.
20. Opawale FO, Burgess DJ,. Influence of interfacial properties of lipophilic surfactants on water-in-oil emulsion stability. J Colloid Interface Sci 1998; 197: 142-150.
21. Constantinides PP, Scalart J-P,. Formulation and physical characterization of water-in-oil microemulsions containing long- versus medium-chain glycerides. Int J Pharm 1997; 158: 57-68.
22. Hunter RJ,. Zeta Potential in Colloid Science: Principles and Applications. London: Academic Press, 1988.
23. Rabinovich-Guilatt L, etal. Extensive surface studies help to analyse zeta potential data: the case of cationic emulsions. Chem Phys Lipids 2004; 131: 1-13.
24. Klang SH, etal. Physicochemical characterization and acute toxicity evaluation of a positively-charged submicron emulsion vehicle. J Pharm Pharmacol 1994; 46: 986-993.
25. Furrer P, etal. Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm 2002; 53: 263-280.
26. Baudouin C, etal. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010; 29: 312-334.
27. Baudouin C,. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 2008; 86: 716-726.
28. Debbasch C, etal. Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci 2001; 42: 642-652.
29. Pisella PJ, etal. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004; 45: 1360-1368.
30. Jaenen N, etal. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007; 17: 341-349.
31. Ammar DA, etal. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofzia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther 2010; 27: 837-845.
32. Kahook MY, Ammar DA,. In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells. J Ocul Pharmacol Ther 2010; 26: 259-263.
33. Ammar DA, Kahook MY,. Effects of glaucoma medications and preservatives on cultured human trabecular meshwork and non-pigmented ciliary epithelial cell lines. Br J Ophthalmol 2011; 95: 1466-1469.
34. EMEA. Emea Public Statement on Antimicrobial Preservatives in Ophthalmic Preparations for Human Use-Emea/622721/2009. 2009.
35. Freeman PD, Kahook M,. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Expert Rev Ophthalmol 2009; 4: 59-64.
36. Liang H, etal. Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits. Mol Vis 2008; 14: 204-216.
37. Smith MJ, etal. Method for the measurement of the diffusion coefficient of benzalkonium chloride. Water Res 2002; 36: 1423-1428.
38. Bague S, etal. Oil-in-Water Type Emulsion with Low Concentration of Cationic Agent and Positive Zeta Potential, Novagali Pharma. Patent No.: US 8298568, 2006.
39. Rabinovich L, etal. Emulsion Compositions Containing Quaternary Ammonium Compounds, Novagali Pharma. Patent No.: US 7973081, 2008.
40. Vlachy N, etal. Determining the cytotoxicity of catanionic surfactant mixtures on HeLa cells. Colloids Surf B Biointerfaces 2009; 70: 278-280.
41. Kurup TRR, etal. Preservative requirements in emulsions. Pharm Acta Helv 1992; 67: 204-208.
42. Kazmi SJ, Mitchell AG,. Preservation of solubilized and emulsified systems I: correlation of mathematically predicted preservative availability with antimicrobial activity. J Pharm Sci 1978; 67: 1260-1266.
43. Sznitowska M, etal. Physicochemical screening of antimicrobial agents as potential preservatives for submicron emulsions. Eur J Pharm Sci 2002; 15: 489-495.
44. Macha S, Mitra AK,. Ocular disposition of ganciclovir and its monoester prodrugs following intravitreal administration using microdialysis. Drug Metab Dispos 2002; 30: 670-675.
45. Abdulrazik M, etal. Ocular delivery of cyclosporin A. II. Effect of submicron emulsion's surface charge on ocular distribution of topical cyclosporin A. STP Pharma Sci 2001; 11: 427-432.
46. Daull P, etal. Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine a cationic emulsions to pigmented rabbits. Cornea 2013; 32: 345-354.
47. Daull P, etal. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models. J Ocul Pharmacol Ther 2012; 28: 515-523.
48. Baudouin C, de Lunardo C,. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol 1998; 82: 39-42.
49. Ishibashi T, etal. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma 2003; 12: 486-490.
50. Ciancaglini M, etal. Conjunctival modifications in ocular hypertension and primary open angle glaucoma: an in vivo confocal microscopy study. Invest Ophthalmol Vis Sci 2008; 49: 3042-3048.
51. Amrane M, etal. The Influence on Seasonality and Subtype in Vernal Keratoconjunctivitis (Vkc) Patients in a Randomized Clinical Trial Investigating Nova22007, a Preservative-Free Cyclosporine Cationic Emulsion. Fort Lauderdale: ARVO, 2012.
52. Liang H, etal. Ocular safety of cationic emulsion of cyclosporine in an in vitro corneal wound healing model and an acute in vivo rabbit model. Mol Vis 2012; 18: 2195-2204.
53. Liang H, etal. Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay. Mol Vis 2009; 15: 1690-1699.
54. Daull P, Garrigue JS,. Preservative-free cationic nanoemulsion of latanoprost. Ophthalmol Times Eur 2013; 9: 8-10.
55. Liang H, etal. In vitro and in vivo evaluation of a preservative-free cationic emulsion of latanoprost in corneal wound healing models. Cornea 2012; 31: 1319-1329.
56. Mundorf TK,. Treat glaucoma patients globally. Adv Ocul Care 2011; 71-72.
57. Godfrey DA,. Glaucoma: what's next? Ophthalmol Times 2011; 42-43.
58. Abelson MB, Lafond A,. Glaucoma and dry eye: a tough combo. Rev Ophthalmol 2011; 108-111.
59. Amrane M, etal. The Effect of Vekacia® (Unpreserved Cyclosporine Cationic Emulsion) on Severe Corneal Involvement in Patients with Vernal Keratoconjunctivitis Participating in a Randomized, Parallel Group Controlled, Clinical Trial. Genève: SOE, 2011.
60. Amrane M, etal. Efficacy of Cationorm Preservative-Free Cationic Emulsion Versus Refresh in Dry Eye Disease (Ded) Patients with/without Meibomian Gland Dysfunction (Mgd). Kenchoji, Kamakura, Japan: TFOS Asia, 2012.
61. Luo L, etal. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens 2005; 31: 186-193.
62. Li DQ, etal. Stimulation of matrix metalloproteinases by hyperosmolarity via a jnk pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2004; 45: 4302-4311.
63. Daull P, etal. Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping. Nice: EVER, 2012.
64. Filion MC, Phillips NC,. Anti-inflammatory activity of cationic lipids. Br J Pharmacol 1997; 122: 551-557.